韦兹曼尼亚凝血剂BC01补充剂通过调节肠道微生物群来改善功能性便秘:一个随机的,安慰剂控制的临床研究
Yihui Xu1, Yongli Zhang2, Fenfang Yue3
1Traditional Chinese Medicine Department, Affiliated Kunshan Hospital of Jiangsu University, Kunshan, China.
Medicine
|December 30, 2025
概括
在一项随机试验中,韦兹曼尼亚凝血剂BC01 (BC01) 有效改善了功能性便秘症状和生活质量. 这种益生菌还积极改变了肠道微生物群组成和短链脂肪酸水平,没有任何不良事件.
科学领域:
- 胃肠病学 胃肠病学
- 微生物学 微生物学
- 临床营养学 临床营养学
背景情况:
- 功能性便秘是一种常见的胃肠道疾病,治疗选择有限.
- 益生菌为治疗便秘提供了一个有希望的治疗途径.
- 维兹曼尼亚凝血菌BC01 (BC01) 是一种安全的益生菌菌株,对便秘有潜在的益处.
研究的目的:
- 评估韦兹曼尼亚凝血剂BC01 (BC01) 在治疗功能性便秘方面的疗效.
- 评估BC01对相关胃肠道症状和生活质量的影响.
- 研究BC01对便微生物群和短链脂肪酸的影响.
主要方法:
- 一个随机,双盲,安慰剂对照试验,涉及113名功能性便秘患者 (罗马四号标准).
- 患者接受BC01 (5 × 10^9 CFU/d) 或安慰剂21天.
- 测量结果包括便秘症状 (罗马IV,疏散日记),临床改善 (克利夫兰分数,布里斯托尔便尺度,GIQLI),短链脂肪酸和便微生物群 (16SrRNA测序).
主要成果:
- 补充BC01显著改善了布里斯托尔便量表和胃肠道生活质量指数得分,同时降低了克利夫兰得分.
- 用BC01治疗导致乙酸和同黄油酸水平增加.
- BC01调节了肠道微生物群,增加了有益的细菌 (Bacteroides,Bifidobacterium,Roseburia) 并减少了有害的细菌 (Firmicutes,Proteobacteria,Blautia).
- 在试验期间没有报告任何不良事件.
结论:
- 威兹曼尼亚凝血菌BC01 (BC01) 显示出功能性便秘的显著治疗潜力.
- BC01改善了便秘症状,肠道微生物群组成和生活质量.
- BC01代表了一种安全有效的益生菌选择,用于管理功能性便秘.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
664
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
664
Chronic Bowel Disorders: Introduction
721
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
721
Drugs for Treatment of Diarrhea-Predominant IBS
590
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
590
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
703
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
703
Irritable Bowel Syndrome III: Medical and Nursing Management
608
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
608
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
604
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
604


